Kongsema et al. [12] reported that RNF168 can trigger the ubiquitination and degradation of FOXM1 and other proteins, increasing the sensitivity of tumor cells to chemotherapy drugs, suggesting that RNF168 acts as a potential oncogene. This evidence concerns the gene RNF168 and neoplasm.